Raymond James & Associates Genprex, Inc. Transaction History

Raymond James & Associates

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 02, 2021	SELL	$2.59 - $3.36 $38,073 - $49,392	-14,700 Closed	0 $0
Q2 2021 Aug 11, 2021	SELL	$3.11 - $4.87 $31,100 - $48,700	-10,000 Reduced 40.49%	14,700 $49,000
Q1 2021 May 14, 2021	BUY	$3.66 - $7.67 $9,150 - $19,175	2,500 Added 11.26%	24,700 $106,000
Q4 2020 Feb 12, 2021	BUY	$3.03 - $5.51 $36,360 - $66,120	12,000 Added 117.65%	22,200 $92,000
Q3 2020 Nov 04, 2020	BUY	$2.9 - $4.29 $29,580 - $43,758	10,200 New	10,200 $34,000

600

Ticker GNPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,300
Market Cap $76.8M
Description
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.